Previous Close | 0.98 |
1-Year Change | -7.55% |
6-Months Change | -44.63% |
3-Months Change | -42.01% |
Moving Avg (50d) | 1.6134 |
Moving Avg (200d) | 1.8907 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 354.3M |
Beta (3-Years) | 1.66 |
Revenue Growth (ttm) | 884.75% |
Net Profit Margin (ttm) | -4138.32% |
Return On Assets (ttm) | -67.39% |
EPS (ttm) | -0.75 |
PE Ratio (ttm) | -1.31 |
Dividend Yield | % |
Asset Description: | Lexicon Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-10-22 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.826 | 0.851 | 0.867 | 0.891 | 0.932 | 0.972 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening... Wikipedia